Additionally, juglone administration resulted in a reduction in heart‐to‐body weight ratio, infarction size, and normalization of cardiac marker enzymes, including cardiac troponin I (cTnI), creatine phosphokinase (CPK), creatine kinase‐MB (CK‐MB), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). The gene discussed is TNNI3; the disease is infarction.